TBK1 and colorectal carcinoma: The CRC cells seemed to respond directly to TBK1-targeted drugs, several studies have reported the application of Amlexanox in cancer treatment and metabolism dysfunction, indicating the potential for adjuvant CRC therapy 40-43.